This review is part of the review series on host-pathogen interactions.
Emerging therapies for the treatment of hepatitis C
Article first published online: 16 SEP 2013
© 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
EMBO Molecular Medicine
Total views since publication: 196
How to Cite
Lange, C. M., Jacobson, I. M., Rice, C. M. and Zeuzem, S. (2013), Emerging therapies for the treatment of hepatitis C. EMBO Mol Med. doi: 10.1002/emmm.201303131
- Article first published online: 16 SEP 2013
- Manuscript Accepted: 14 AUG 2013
- Manuscript Revised: 12 AUG 2013
- Manuscript Received: 13 JUN 2013
- directly acting antiviral agents;
- hepatitis C virus;
- NS3-4A protease inhibitor;
- NS5B polymerase inhibitor
Opportunities to treat infection with hepatitis C virus (HCV) are evolving rapidly. From the introduction of interferon-α monotherapy in 1992 to the approval of telaprevir- and boceprevir-based triple therapies with pegylated interferon-α and ribavirin in 2011, the chances of curing patients infected with HCV genotype 1 have improved from <10% to approximately 70%. Significant further improvements are on the horizon, which may well cure virtually all hepatitis C patients with an all-oral, interferon-free regimen in the very near future. These exciting developments are reviewed in the present article.